Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
about
Tamoxifen regulation of sphingolipid metabolism--Therapeutic implicationsRole of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships.The effects of tamoxifen on immunity.In vitro and in vivo effects of tamoxifen against larval stage Echinococcus granulosusGaucher's disease and cancer: a sphingolipid perspectiveP-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.Tamoxifen inhibits acidification in cells independent of the estrogen receptorResistance to cancer chemotherapy: failure in drug response from ADME to P-gp.Challenges and Potential for Ovarian Preservation with SERMs.Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.Glioblastoma entities express subtle differences in molecular composition and response to treatmentEsters of the marine-derived triterpene sipholenol A reverse P-GP-mediated drug resistance.The siRNA-mediated downregulation of N-Ras sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors.Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B.Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines.Extracellular acidification elicits a chloride current that shares characteristics with ICl(swell).Tamoxifen-resistant glioma-cell sub-populations are characterized by increased migration and proliferation.Inhibition of voltage-gated cationic channels in rat embryonic hypothalamic neurones and C1300 neuroblastoma cells by triphenylethylene antioestrogens.Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells.Tamoxifen inhibits nitrobenzylthioinosine-sensitive equilibrative uridine transport in human MCF-7 breast cancer cells.The effects of tamoxifen and toremifene on bone cells involve changes in plasma membrane ion conductance.Neither lipophilicity nor membrane-perturbing potency of phenothiazine maleates correlate with the ability to inhibit P-glycoprotein transport activity.Antiangiogenic and hypolipidemic activity of coenzyme Q10 supplementation to breast cancer patients undergoing Tamoxifen therapy.Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates.Classification analysis of P-glycoprotein substrate specificity.Recent advances in understanding the molecular mechanisms of tamoxifen action.Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis.The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation.
P2860
Q28084270-CE422F81-3108-4280-8ABD-3A63B5D1A583Q30274798-5092D377-3BC9-4289-9F79-59CEE81F9483Q33716375-DFEA0888-D9A1-4D73-9770-71B23B387C20Q33989185-1E259EB8-1B19-4B38-B9CD-5DBDB9ECA631Q34057335-6A3CED7F-63C4-48F1-9C4E-50AF95169A17Q34333982-A5789844-8464-45CD-8DCB-4978D061CF96Q35057879-05CED09E-1DAA-459B-890F-E4193B54448FQ35126990-807D69C8-7412-48BA-887D-199C0A873644Q35852614-312670EE-5D03-4CBC-844A-729690E005F9Q36282795-0E8E5CFF-580E-4663-861E-ACD6809AC5A3Q36392653-D1D79836-02D9-433F-A7C4-258E294765ABQ36588606-571226A0-ABFC-4519-9FFF-F015DD87ADC3Q36704209-C6584717-ACBA-4F9F-9B44-636EB08B0F18Q36915143-29C10949-2DC9-4BB9-8E9A-0C880DB64EF8Q38697178-BF23F2AF-52F2-4A08-B2F8-5610FC6A89AFQ38887070-C05DCEDF-5D8A-448E-8663-BE29D5D31166Q39011419-42839E9C-55B2-46FC-A8FE-00F004AD5A41Q40092859-97791ED5-7ECA-4488-83EB-C46C7984D9AAQ40516820-BE278975-B890-45EE-A09A-15B4FEC79A33Q40526309-72B2944B-44CD-483E-B243-60BD6788BAA1Q40882291-BD7DFC00-8F28-4A26-9215-83DB777519DBQ41008001-4BFE2C40-720F-453A-82C2-171EB88BA340Q41151987-2C8335FC-8C69-49BB-8182-9A0EF1A414EAQ41681702-DF19AC39-3A9C-4B39-8263-705E85161AAAQ42540015-75698608-BB47-4C97-AD0F-CFD7B86C1212Q44348519-C51EC34F-BAA9-48C7-83F1-4D2E7AF0B5BEQ44440276-162B18AC-BE45-4157-8BCA-79C4E906F78EQ46190472-40B68AB4-627F-4B19-B1CA-F69693FEB876Q47100454-11D45C2F-73AE-4587-BB8F-206277325850Q47326688-A66F7C24-56DE-4204-A872-BE27236B3631Q47785739-8E6F5197-BEA5-4662-9268-4F784871A7D6Q53970603-16DF60AF-2AA5-41AB-A2E7-82B0AF46818FQ54127917-5F46F2E2-65AF-4927-9A41-3CEDDF60814D
P2860
Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
@ast
Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
@en
type
label
Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
@ast
Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
@en
prefLabel
Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
@ast
Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
@en
P2860
P356
P1476
Interaction of tamoxifen with the multidrug resistance P-glycoprotein
@en
P2093
C F Higgins
P2860
P2888
P304
P356
10.1038/BJC.1995.59
P407
P577
1995-02-01T00:00:00Z